What is HC Wainwright's Forecast for SNDX FY2025 Earnings?

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) - Equities researchers at HC Wainwright reduced their FY2025 EPS estimates for shares of Syndax Pharmaceuticals in a research report issued on Tuesday, March 4th. HC Wainwright analyst E. White now expects that the company will post earnings of ($3.86) per share for the year, down from their previous forecast of ($3.76). HC Wainwright currently has a "Buy" rating and a $51.00 target price on the stock. The consensus estimate for Syndax Pharmaceuticals' current full-year earnings is ($3.72) per share. HC Wainwright also issued estimates for Syndax Pharmaceuticals' FY2026 earnings at ($2.97) EPS.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its earnings results on Monday, March 3rd. The company reported ($1.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.79). The company had revenue of $7.68 million for the quarter, compared to analyst estimates of $86.32 million.

Several other analysts have also recently weighed in on SNDX. Scotiabank dropped their price target on Syndax Pharmaceuticals from $18.00 to $16.00 and set a "sector perform" rating for the company in a report on Wednesday, January 8th. JPMorgan Chase & Co. lifted their target price on Syndax Pharmaceuticals from $35.00 to $39.00 and gave the stock an "overweight" rating in a report on Tuesday, March 4th. Citigroup decreased their price target on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating on the stock in a research note on Tuesday, March 4th. Finally, StockNews.com downgraded shares of Syndax Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, November 23rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Syndax Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $36.00.

Remove Ads

Syndax Pharmaceuticals Trading Down 6.6 %

Shares of SNDX traded down $0.89 during mid-day trading on Thursday, reaching $12.53. The company's stock had a trading volume of 1,873,839 shares, compared to its average volume of 2,344,236. The business has a 50-day simple moving average of $14.33 and a two-hundred day simple moving average of $16.58. Syndax Pharmaceuticals has a 1-year low of $12.06 and a 1-year high of $25.07. The stock has a market cap of $1.08 billion, a P/E ratio of -3.45 and a beta of 0.92.

Insiders Place Their Bets

In related news, CFO Keith A. Goldan sold 3,777 shares of the business's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $58,543.50. Following the sale, the chief financial officer now directly owns 90,746 shares in the company, valued at approximately $1,406,563. The trade was a 4.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Neil Gallagher sold 4,618 shares of the company's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $71,579.00. Following the sale, the insider now owns 85,095 shares in the company, valued at $1,318,972.50. The trade was a 5.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 21,683 shares of company stock valued at $336,087. Company insiders own 4.10% of the company's stock.

Hedge Funds Weigh In On Syndax Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. R Squared Ltd purchased a new position in Syndax Pharmaceuticals in the 4th quarter worth $26,000. Quantbot Technologies LP purchased a new stake in Syndax Pharmaceuticals in the third quarter worth about $49,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Syndax Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company's stock worth $58,000 after purchasing an additional 541 shares during the last quarter. Virtus ETF Advisers LLC boosted its stake in Syndax Pharmaceuticals by 18.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company's stock valued at $70,000 after purchasing an additional 827 shares during the last quarter. Finally, Cape Investment Advisory Inc. lifted its position in Syndax Pharmaceuticals by 157.1% during the fourth quarter. Cape Investment Advisory Inc. now owns 6,427 shares of the company's stock valued at $85,000 after purchasing an additional 3,927 shares during the period.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).